Modality
mRNA
MOA
PRMT5i
Target
RET
Pathway
RAS/MAPK
Ewing SarcomaMG
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
Jun 2018
→ Feb 2027
Phase 3Current
NCT05757871
1,275 pts·Ewing Sarcoma
2018-06→2027-02·Completed
1,275 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-1911mo awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Complet…
Catalysts
Ph3 Readout
2027-02-19 · 11mo away
Ewing Sarcoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05757871 | Phase 3 | Ewing Sarcoma | Completed | 1275 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-5389 | Roche | Preclinical | RET | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |